Citalopram

Afro-Americans have a poorer response to citalopram compared to Caucasians.
There were overall significant differences (unadjusted data) between Caucasian (self-identied as US 'white) and Afro-Americans (self-identied as US 'blacks') participants with nonpsychotic depressive disorder who achieved remission on the clinician-rated HRSD17 (Caucasian remission rate = 30.1%; Afro-American remission rate = 18.6%; p<0.0001) and the participant-rated QIDS-SR16 (Caucasian remission rate = 36.1%; Afro-American remission rate = 22.2%; p<0.0001).
After adjustment (see note 1) the differences in remission between Caucasians and Afro-Americans disappeared in the HRSD17 but remained in the QIDS-SR16 (odds ratio Caucasian = 1; odds Afro-American = 0.698; p=0.0183).

1. Hispanic Americans do not have a poorer response to citalopram compared to Caucasians.
There were overall significant differences (unadjusted data) between Caucasian (self-identied as US 'white) and Hispanic Americans (self-identied as US 'hispanics') participants with nonpsychotic depressive disorder who achieved remission on the clinician-rated HRSD17 (Caucasian remission rate = 30.1%; Hispanic American remission rate = 24.2%; p=0.029) and the participant-rated QIDS-SR16 (Caucasian remission rate = 36.1%; Hispanic American remission rate = 30.4%; p=0.0475). However after adjustment (see note 1) the differences in remission between Caucasians and Hispanic Americans disappeared Lesser, 2007.

  1. You are here:  
  2. Home
  3. Psychoactive drugs
  4. Antidepressants
  5. Citalopram

Search